Mod GRF 1-29
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A modified GHRH fragment that triggers pulsatile growth hormone release. The case is mostly mechanistic: preserved pulsatility and GHRP synergy have moderate support; claimed gains in body composition and sleep are low or speculative. Human safety data are minimal, and the resulting IGF-1 rise carries an unresolved, theoretical tumor concern. Not FDA-approved; most supply consists of unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(5)
Dose-dependent increase in growth hormone levels
SpeculativeSustained multi-day GH rise is documented for CJC-1295 with DAC, not for Mod GRF 1-29.
Preservation of natural GH pulsatility (unlike exogenous GH injection)
MediumMechanistically expected from the GHRH-analog class; not directly measured for this specific compound.
Synergistic GH release with GHRPs (Ipamorelin, GHRP-6)
MediumHuman trials show greater GH release combining GHRH and GHRP-6, mostly in patient populations.
Evidence limits
- Evidence Level
- Limited Evidence
Direct clinical trial data for tetrasubstituted Mod GRF 1-29 is limited. The strongest evidence comes from the CJC-1295 (with DAC) RCTs showing sustained GH/IGF-1 elevation in healthy adults. Sermorelin (unmodified GRF 1-29) had sufficient clinical data for prior FDA approval. The specific tetrasubstituted form is widely used based on GHRH-class pharmacology and mechanistic rationale, with substantial anecdotal and clinical practice evidence but limited published controlled trials of the exact compound.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Injection site reactions (redness, swelling, pain)
HighFlushing and warmth
LowWater retention and joint stiffness
ModeratePotential impact on blood glucose regulation
ModerateTheoretical tumor growth promotion (via IGF-1 elevation)
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.